Gilead Provides Update on Phase 3 EVOKE-01 Study
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in…#gileadsciencesinc #phase3 #nsclc #gilead #trodelvy #merdadparsey #phd #gileadsciences #phase2 #worldconference (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2024 Category: Consumer Health News Source Type: news

Why Is HIV Drug Giant Gilead Stock Trading Lower Today?
Gilead Sciences Inc GILD said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or…#nsclc #trop2 #gild (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2024 Category: Consumer Health News Source Type: news

Docetaxel Use Associated With Significant Reduction in Prostate Cancer Death in Very Poor Prognostic Group
A meta-analysis of five prospective randomized clinical trials (RCTs) found that adding docetaxel to standard-of-care (SOC) treatment was associated with a 70% reduction in death from prostate cancer-specific mortality (PCSM). (Source: BWH News)
Source: BWH News - November 1, 2023 Category: Hospital Management Source Type: news

Venus Remedies gets marketing authorization from Saudi Arabia for chemotherapy drug Docetaxel
The development comes three months after the company received good manufacturing practices (GMP) certification from the Saudi Food and Drug Authority (SFDA) for all its production facilities at its unit in Baddi, Himachal Pradesh. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 1, 2023 Category: Pharmaceuticals Source Type: news

Janssen Marks First Approval Worldwide for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
BEERSE, Belgium, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for AKEEGA® (niraparib and abiraterone acetate [AA]), in the form of a dual action tablet (DAT), given with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.2Prostate cancer is the most common cancer in men in Europe, and the sixth-highest cause of cancer-related death worldwide.1...
Source: Johnson and Johnson - April 21, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news

Guideline Updated for Initial Management of Advanced Prostate Cancer
WEDNESDAY, April 12, 2023 -- For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen deprivation therapy (ADT), and doublet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2023 Category: Pharmaceuticals Source Type: news

Gemcitabine, Docetaxel a Viable Alternative to BCG in Bladder Cancer
MONDAY, March 13, 2023 -- For patients with non-muscle invasive bladder cancer (NMIBC), gemcitabine and docetaxel therapy is associated with less high-grade disease recurrence, according to a study published online Feb. 28 in JAMA Network Open. Ian... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2023 Category: Pharmaceuticals Source Type: news

Gemcitabine-Docetaxel Effective Alternative to BCG in NMIBC Gemcitabine-Docetaxel Effective Alternative to BCG in NMIBC
The chemotherapy duo performed better than expected as a stand-in for bacillus Calmette-Gu érin (BCG), which is the gold standard for non–muscle-invasive bladder cancer but is currently in short supply.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 7, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Alembic Pharma gets USFDA nod to market generic cancer drug
Docetaxel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of head and neck. According to IQVIA data, Docetaxel injection has an estimated market size of USD 11 million in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2023 Category: Pharmaceuticals Source Type: news

Janssen Receives Positive CHMP Opinion for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
BEERSE, Belgium, 24 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorisation for AKEEGA® (niraparib and AA), in the form of a DAT, given with P or prednisolone, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.[1]Niraparib is a highly selective poly adenosine diphosphate-ribose polymerase (PARP) inhibi...
Source: Johnson and Johnson - February 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Rucaparib Benefit in BRCA+ Prostate Cancer Confirmed Rucaparib Benefit in BRCA+ Prostate Cancer Confirmed
For patients with metastatic castration-resistant prostate cancer with BRCA alterations, rucaparib doubled progression-free survival as compared with docetaxel, abiraterone, or enzalutamide.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Docetaxel as Alternative to Cisplatin for H & N Radiotherapy Docetaxel as Alternative to Cisplatin for H & N Radiotherapy
Investigators report the first phase 3 results for a radiosensitizing alternative to cisplatin for patients who cannot tolerate it.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adding Docetaxel to RT Improves Survival in Cisplatin-Ineligible Head & Neck Cancer
(MedPage Today) -- Adding docetaxel to radiation therapy (RT) improved survival outcomes in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase III randomized trial showed. At a median follow-up of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 4, 2023 Category: Hematology Source Type: news

CHMP recommends Bayer ’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel for marketing authorization in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). (Source: World Pharma News)
Source: World Pharma News - January 30, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

High Febrile Neutropenia Risk With Docetaxel in Prostate Cancer High Febrile Neutropenia Risk With Docetaxel in Prostate Cancer
The risk is high enough to consider routine febrile neutropenia prophylaxis in patients with metastatic castration-resistant disease. The study was published as a preprint and has not been peer reviewed.First Look (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 2, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news